Skip to content

Hans H Maurer

16 papers in the library · 921 citations · publishing 2002-2019

Papers

Sort Most recent Most cited

Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases.

Drug Testing and Analysis February 1, 2019 Lea Wagmann, Simon D. Brandt, Alexander Stratford et al. 26 citations

Psychoactive substances of the 2C-series (2Cs) are phenethylamine-derived designer drugs that can induce psychostimulant and hallucinogenic effects. Chemically, the classic 2Cs contain two methoxy groups in positions 2 and 5 of the phenyl ring, whereas substances of the so-called FLY series contain rigidified methoxy groups integrated in a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran core. One...

DOI: 10.1002/dta.2494 (opens in new tab) Full text (opens in new tab) Ic50 value Drugs of abuse Monoamine oxidase inhibition Phenethylamines +10

Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.

Toxicology Letters March 15, 2018 Achim T. Caspar, Markus R Meyer, Hans H Maurer

A huge number of new chemical derivatives of known drugs of abuse, so-called new psychoactive substances (NPS), are sold and consumed without prior preclinical and clinical testing. For assessing the elimination behaviors, determination of the kinetic constants Km and Vmax of the cytochrome P450 (CYP) isoforms involved in the hepatic metabolism of NPS could help to predict their contributions...

DOI: 10.1016/j.toxlet.2017.12.017 (opens in new tab) Full text (opens in new tab) Michaelis-menten kinetic Nbome Relative activity factor Substrate depletion approach

In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.

Toxicology Letters April 15, 2017 Lea Wagmann, Simon D. Brandt, Pierce V. Kavanagh et al.

Tryptamines have emerged as new psychoactive substances (NPS), which are distributed and consumed recreationally without preclinical studies or safety tests. Within the alpha-methylated tryptamines, some of the psychoactive effects of the prototypical alpha-methyltryptamine (AMT) have been described decades ago and a contributing factor of its acute toxicity appears to involve the inhibition of...

DOI: 10.1016/j.toxlet.2017.03.007 (opens in new tab) Full text (opens in new tab) Drugs of abuse Ic50 value Lc–hr-ms/ms Mao inhibition

Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Drug Testing and Analysis 2017 Simon D. Brandt, Pierce V. Kavanagh, Geraldine Dowling et al. 16 citations

Many N,N-dialkylated tryptamines show psychoactive properties in humans and the number of derivatives involved in multidisciplinary areas of research has grown over the last few decades. Whereas some derivatives form the basis of a range of medicinal products, others are predominantly encountered as recreational drugs, and in some cases, the areas of therapeutic and recreational use can...

DOI: 10.1002/dta.1974 (opens in new tab) Full text (opens in new tab) Dalt New psychoactive substances Tryptamines Forensic chemistry +2

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.

Toxicology Letters November 17, 2015 Julia Dinger, Campbell Woods, Simon D. Brandt et al.

New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition potential before consumption. Therefore, this potential was explored for tryptamine-derived NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl tryptamines (DMTs), diallyl tryptamines (DALTs), and diisopropyl tryptamines (DiPTs) using test substrates preferred by the Food and Drug...

Absorption, Distribution, Metabolism and Excretion Pharmacogenomics of Drugs of Abuse

Pharmacogenomics February 1, 2011 Markus R Meyer, Hans H Maurer 107 citations

Pharmacologic and toxic effects of xenobiotics, such as drugs of abuse, depend on the genotype and phenotype of an individual, and conversely on the isoenzymes involved in their metabolism and transport. The current knowledge of such isoenzymes of frequently abused therapeutics such as opioids (oxycodone, hydrocodone, methadone, fentanyl, buprenorphine, tramadol, heroin, morphine and codeine),...

DOI: 10.2217/pgs.10.171 (opens in new tab) Pharmacology Alfentanil Hydrocodone Oxycodone +6

Metabolism of designer drugs of abuse: an updated review.

Current Drug Metabolism June 1, 2010 Markus R Meyer, Hans H Maurer 112 citations

This paper reviews the metabolism of new designer drugs of abuse that have emerged on the black market during the last years and is an update of a review published in 2005. The presented review contains data concerning the so-called 2C compounds (phenethylamine type) such as 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B), 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I),...

DOI: 10.2174/138920010791526042 (opens in new tab) Full text (opens in new tab) Drug metabolism Pharmacokinetics Biotransformation Metabolites +19

Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers.

Toxicology Letters October 8, 2009 Markus R Meyer, Frank T. Peters, Hans H Maurer

3,4-Methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) are chiral designer drugs distributed on the illicit drug market and they are also N-dealkyl metabolites of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Adam), 3,4-methylenedioxyethylamphetamine (MDEA, Eve), and N-methyl-benzodioxolyl-butanamine (MBDB, Eden), respectively. MDA and BDB are mainly metabolized via...

Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Drug Metabolism and Disposition October 2009 Melanie Mueller, Jie Yuan, Anne Felim et al.

The mechanism by which the recreational drug (+/-)-3,4-methylenedioxymethamphetamine (MDMA) destroys brain serotonin (5-HT) axon terminals is not understood. Recent studies have implicated MDMA metabolites, but their precise role remains unclear. To further evaluate the relative importance of metabolites versus the parent compound in neurotoxicity, we explored the relationship between...

Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.

Biochemical Pharmacology June 1, 2009 Markus R Meyer, Frank T. Peters, Hans H Maurer

In the present study, cytochrome P450 isozymes (P450) involved in the stereoselective metabolism of the designer drug N-methyl-benzodioxolyl-butanamine (MBDB, Eden) were identified for the first time. Demethylenation and N-demethylation of racemic MBDB as well as its single enantiomers were investigated using cDNA-expressed insect cell microsomes. After incubation of MBDB, the two resulting...

Enantioselectivity in the Methylation of the Catecholic Phase I Metabolites of Methylenedioxy Designer Drugs and Their Capability To Inhibit Catechol-O-methyltransferase-Catalyzed Dopamine 3-Methylation

Chemical Research in Toxicology May 22, 2009 Markus R Meyer, Hans H Maurer 39 citations

The designer drugs R,S-3,4-methylenedioxy-methamphetamine (MDMA, Ecstasy), R,S-3,4-methylenedioxy-ethylamphetamine (MDEA, Eve), and R,S-N-methyl-benzodioxolyl-butanamine (MBDB, Eden) are chiral compounds, and their in vitro and in vivo metabolism is enantioselective with a preference for the S-enantiomer caused in part by P450-mediated demethylenation. As the elimination of the catecholamine...

DOI: 10.1021/tx900134e (opens in new tab) Methylenedioxy Methylation Catechol-o-methyl transferase Microsome +5

Analysis of toxic alkaloids in body samples.

Forensic Science International March 10, 2009 Jochen Beyer, Olaf H Drummer, Hans H Maurer 118 citations

Many plants contain toxic alkaloids which may be dangerous to humans. Despite the large number of poisonous plants, cases of fatal plant poisonings are relatively rare. The frequencies of poisonings and the plants involved are often regionally specific. Plant poisonings can be aggregated into three categories: unintended ingestions, intended ingestions, and poisoning due to abuse of plant...

DOI: 10.1016/j.forsciint.2008.12.006 (opens in new tab) Full text (opens in new tab) Dangerous plant-derived alkaloids Toxic compounds Aconitine Scopolamine +7

Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series).

Biochemical Pharmacology January 15, 2007 Denis S Theobald, Hans H Maurer 59 citations

In recent years, several compounds of the phenethylamine-type (2C-series) have entered the illicit drug market as designer drugs. In former studies, the qualitative metabolism of frequently abused 2Cs (2C-B, 2C-I, 2C-D, 2C-E, 2C-T-2, 2C-T-7) was studied using a rat model. Major phase I metabolic steps were deamination and O-demethylation. Deamination to the corresponding aldehyde was the...

DOI: 10.1016/j.bcp.2006.09.022 (opens in new tab) Full text (opens in new tab) Drug metabolism Designer drugs Mao enzymes Drug interactions

Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types

Therapeutic Drug Monitoring March 19, 2004 Hans H Maurer, Thomas Kræmer, Dietmar Springer et al. 147 citations

Designer drugs of the amphetamine type (eg, MDMA, MDEA, MDA), of the new benzyl or phenyl piperazine type (eg, BZP, MDBP, mCPP, TFMPP, MeOPP), or of the pyrrolidinophenone type (eg, PPP, MOPPP, MDPPP, MPPP, MPHP) have gained popularity and notoriety as rave drugs. These drugs produce feelings of euphoria and energy and a desire to socialize. Although in the corresponding drug scene designer...

Concentrations and Ratios of Amphetamine, Methamphetamine, MDA, MDMA, and MDEA Enantiomers Determined in Plasma Samples from Clinical Toxicology and Driving Under the Influence of Drugs Cases by GC-NICI-MS*

Journal of Analytical Toxicology November 1, 2003 Frank T. Peters, Nele Samyn, Martin Wahl et al. 65 citations

Enantiomers of amphetamine (AM), methamphetamine (MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) exhibit different pharmacological properties. This may be important for the interpretation of analytical results. Plasma samples were analyzed using validated negative ion chemical ionization gas chromatography-mass...

DOI: 10.1093/jat/27.8.552 (opens in new tab) Full text (opens in new tab) MDMA Methamphetamine Pharmacology Forensic toxicology +2

Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives

Therapeutic Drug Monitoring April 1, 2002 Thomas Kræmer, Hans H Maurer 232 citations

This paper reviews the toxicokinetics of amphetamines. The designer drugs MDA (methylenedioxy-amphetamine, R,S-1-(3;,4;-methylenedioxyphenyl)2-propanamine), MDMA (R,S-methylenedioxymethamphetamine), and MDE (R,S-methylenedioxyethylamphetamine), as well as BDB (benzodioxolylbutanamine; R,S-1-(1;,3;-benzodioxol-5;-yl)-2-butanamine or R,S-1-(3;,4;-methylenedioxyphenyl)-2-butanamine) and MBDB...

DOI: 10.1097/00007691-200204000-00009 (opens in new tab) MDMA Toxicokinetics Methamphetamine Designer drug +4